Can we count on normal PSA levels by age? Regardless of any PSA reference range for different age groups, there’s actually no ‘normal’ prostate-specific antigen level that guarantees you’re free from prostate cancer.
What is a PSA Screening?
A prostate-specific antigen (PSA) screening a simple blood test that measures that assesses your risk of prostate cancer. Generally, your risk of having prostate cancer increases along with your PSA level, and in most men, PSA concentrations rise with age, for various reasons.
Although experts have devised age-adjusted PSA reference ranges to estimate your risk of prostate cancer, there really are no truly normal PSA levels by age. In other words, although PSA can give you an idea of your risk, there’s no guarantee that you have prostate cancer if your PSA rises above a certain mark, nor are you assured of being cancer-free if your PSA remains below a particular threshold.
“Normal” PSA Levels by Age
Historically, a PSA result of less than 4 ng/ml was considered normal, and above that level, doctors recommended a biopsy to check for cancer. But, research has since called this strategy into question.
The concern is that, since PSA cannot identify for certain which men have clinically significant prostate cancer and which men don’t, the screening test may lead to unnecessary biopsies and treatments—all of which carry a risk of serious side effects.
So, because PSA levels naturally increase as you get older, some experts have proposed using age-specific reference ranges in an attempt to identify normal PSA levels by age and reduce the number of unnecessary biopsies.
For instance, in its 2009 best practices statement regarding PSA screening, the American Urological Association (AUA) identified age-specific median PSA levels:
– 0.7 ng/ml for men in their 40’s
– 0.9 ng/ml for men in their 50’s
– 1.2 ng/ml for men in their 60’s
– 1.5 ng/ml for men in their 70’s
The AUA also outlined several published “normal” PSA levels by age, based on ethnicity:
– Ages 40 to 49: 0 to 2.0 ng/ml for Asian- and African-Americans, and 0 to 2.5 ng/ml for Caucasians
– Ages 50 to 59: 0 to 3.0 ng/ml for Asian-Americans, 0 to 4.0 ng/ml for African-Americans, and 0 to 3.5 ng/ml for Caucasians
– Ages 60 to 69: 0 to 4.0 ng/ml for Asian-Americans, and 0 to 4.5 ng/ml for African-Americans and Caucasians
– Ages 70 to 79: 0 to 5.0 ng/ml for Asian-Americans, 0 to 5.5 ng/ml for African-Americans, and 0 to 6.5 ng/ml for Caucasians
In one study, researchers evaluated age-specific PSA cut-off values in 2,225 Austrian men who underwent prostate biopsy because of elevated PSA levels. They found that the following PSA values had the best prostate cancer specificity: 1.7 ng/ml for men age 59 and younger; 2.25 ng/ml for men ages 60 to 69; and 3.25 ng/ml for those age 70 and older.
“Using these adjusted PSA cut-off values, all significant tumors are recognized in all age groups, yet the number of biopsies is reduced,” the researchers wrote (PLoS One, July 28, 2015).
Is There a Safe PSA Level?
Age-adjusted PSA values are one way that may help reduce unnecessary biopsies, but data from the landmark Prostate Cancer Prevention Trial (PCPT) suggest there is no PSA below which the risk of having prostate cancer is zero.
Rather, the risk of prostate cancer follows a continuum, increasing as PSA values rise, the AUA notes.
Based on the PCPT and other research, you have:
– An 8.8 percent chance of having prostate cancer found on a biopsy if your PSA is 1.0 ng/ml or lower
– A 17 percent chance if your PSA is 1.1 to 2.0 ng/ml
– A 23.9 percent chance if your PSA is 2.1 to 3.0 ng/ml
– A 26.9 percent chance if your PSA is 3.1 to 4.0 ng/ml
– A 47 percent chance if your PSA is 4.1 to 10 ng/ml
– A 58.3 percent chance if your PSA is 10.1 ng/ml or higher
Many experts now advocate the use of nomograms and risk calculators—such as those derived from the PCPT and the European Randomized Study of Screening for Prostate Cancer—that incorporate PSA and other factors to compile an individualized risk assessment.
Augmenting the PSA Test
In an effort to fine-tune prostate cancer screening, your physician may use several derivatives of PSA in addition to your total PSA level. One of these tests is PSA velocity, which calculates the rate at which your PSA rises over time. (A related calculation is PSA doubling time, the amount of time it takes the PSA level to double.)
Your doctor also may consider a free-PSA test, which measures whether the PSA in the blood is floating free on its own or is attached to a protein molecule. Benign conditions tend to produce more free PSA, while cancer tends to produce the attached form. By measuring the ratio of free to attached PSA, doctors get another hint about the cause of an elevated PSA level.
More recent additions to the prostate cancer screening armamentarium incorporate PSA and other prostate-derived substances. One of these tests, the Prostate Health Index (PHI), measures [-2] pro-PSA (an isoform of free PSA) along with total PSA and other forms of free PSA. Research has found that the PHI, a blood test, can outperform total PSA and percentage of free PSA at detecting prostate cancer and predicting clinically significant disease.
Additionally, studies have found that another assay, the 4Kscore, may help predict which men will have more aggressive prostate cancer on biopsy and thus reduce the number of unnecessary biopsies. The test measures blood levels of four prostate-derived proteins:
1. Total PSA
2. Free PSA
3. intact PSA
4. human kallikrein 2
These biomarkers are combined with a patient’s age, digital rectal exam, and biopsy history to calculate the likelihood of finding a high-grade prostate cancer on biopsy. Ask your doctor about these tests to help gauge your risk of having clinically significant prostate cancer on biopsy.
~ For related reading, please visit these posts ~
This article was originally published in 2018. It is regularly updated.
Written by Jim Black and published by University Health News ~ August 2, 2019